Welcome to this week's Chutes and Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Alyssa Huntley (email) and we will feature it here at the end of each week.
Medivation VP moves on to BeiGene after Pfizer buy
BeiGene
Amy Peterson joins as chief medical officer
Medivation continues to make headlines. After being bought out by Pfizer in a huge $14 billion deal, Amy Peterson, Medivation's vice president of clinical development, has decided to move on to BeiGene. BeiGene is working on its own PARP inhibitor. Peterson will take on the chief medical officer of immuno-oncology role at BeiGene, focusing on the development of BGB-A317 and BGB-290, a PD-1 inhibitor and PARP inhibitor respectively. Peterson will also work on other I/O candidates. FierceBiotech article
Zoetis loses one CFO, promotes its own to the vacancy
Zoetis
Zoetis has promoted Glenn David to EVP and CFO
Zoetis has given senior VP of finance operations Glenn David a promotion. David will take on the role of EVP and chief financial officer and will handle the company's financial management, planning and global operations. David will report to CEO Juan Ramón Alaix. David is taking on the role left by Paul Herendeen, who left the company on August 18 to take on a CFO position at a different company. Release
Shanghai Pharmaceuticals loses chairman after three months on the job
Shanghai Pharmaceuticals
Zhou Jie has resigned after three months
After only three months on the job, Zhou Jie has resigned from his post as executive chairman. Jie had replaced Lou Dingbo, who left China's second-largest drugmaker due to personal reasons. The company has insisted that there are no disagreements between Jie and the board and that his leaving is due to completion of work commitments. Jie has also resigned from the chairman and chief executive positions he held at Shanghai Industrial Holdings. FiercePharmaAsia article
Mylan loses Sarah Jessica Parker thanks to EpiPen price hikes
Mylan
Sarah Jessica Parker quits marketing campaign
Sarah Jessica Parker has decided to end her promotional work with Mylan. She explained the decision in an Instagram post, noting that she ended her relationship with the company as a "direct result" of the price hikes on the EpiPen. Parker noted she is "disappointed, saddened and deeply concerned by Mylan's actions," and said she hopes Mylan will take into consideration the "outpouring of voices" from the many people who are dependent on the epinepherine auto-injector. FiercePharmaMarketing article
Many fear job cuts as Takeda makes plans to close Cambridge office. Release
Pharma
> Chris Mathes joins Icagen as chief commercial officer in an effort to drive drug discover and ion channel services. Release
> St. Jude Children's Research Hospital has named James Morgan the scientific director and executive vice president. Release
> Kalytera Therapeutics has named Andrew Salzman to the chief medical officer role, tasking him with advancing drug candidates into human clinical studies. Release
> Moleculin has named Jonathan P. Foster to the execute vice president and chief financial officer roles. Release
> Daryl Gaugler will take on the president role at Spectra BioPharma Selling Solutions. Release
Biotech
> Owlstone Medical has made three appointments to its senior team. Chris Hodkinson joins as VP of business development, Marc van der Schee as lead clinical research scientist, and Hamilton Scanlon as VP of manufacturing. Release
> TapImmune brought on Michael J. Loiacono as the chief financial officer and chief accounting officer. Release
> Edward Ebbers will join Pulse Biosciences as VP and general manager of dermatology products. Release
> Spyryx Biosciences is bringing on Alistair Wheeler as chief medical officer. Release
> ACell has named Brad Adams the VP of sales. Release